EGFR and neoplasm: Whereas genetic mutations on EGFR gene receptor were identified in tumours of patients responding to gefitinib (Lynch et al, 2004; Paez et al, 2004), we also need more easily assessable and clinically available predictive factors for response to gefitinib for daily practice.